共 41 条
- [31] Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)BLOOD, 2019, 134Terpos, EvangelosKastritis, EftathiosHatjiharissi, EvdoxiaKatodritou, EiriniEleutherakis-Papaiakovou, EvangelosVerrou, EvgeniaGavriatopoulou, MariaLeonidakis, AlexandrosNtanasis-Stathopoulos, IoannisDelimpasi, SosanaKyrtsonis, Marie-ChristinePapaioannou, MariaSymeonidis, ArgirisDimopoulos, Meletios A.
- [32] IMPACT OF PRIOR THERAPY (TX) ON THE EFFICACY AND SAFETY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): MM-021 TRIALHAEMATOLOGICA, 2014, 99 : 375 - 375Jin, J.Du, X.Cai, Z.Chen, F.Zhou, D. B.Yu, L.Li, X.Wu, D.Meng, F.Ai, H.Wang, J.Zhang, J.Wortman-Vayn, H.Mei, J.Hou, J.
- [33] Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Fu, WeijunXia, ZhongjunFu, ChengchengChen, WenmingAn, GangCai, ZhenFang, BaijunJing, HongmeiWei, YongqiangWeng, JianyuChang, ChunkangChen, LijuanGao, SujunChen, XiequnLi, FeiLiu, ZhuogangLiu, JingJiao, YingWang, AihuaQiu, Lugui
- [34] Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) plus Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)BLOOD, 2017, 130Qian, XiaozhongNewhall, KathrynTometsko, MarkBjorklund, ChadMa, JianglinBahlis, Nizar J.Siegel, DavidSchiller, Gary J.Samaras, ChristySebag, MichaelBerdeja, Jesus G.Ganguly, SiddharthaMatous, Jeffrey V.Song, Kevin W.Seet, Christopher S.Talamo, GiampaoloSrinivas, ShanthiAcosta-Rivera, MirelisBar, MichaelQuick, DonaldAnz, BertrandFonseca, GustavoReece, DonnaMouro, JorgeAgarwal, AmitZafar, FaizaThakurta, Anjan
- [35] Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (Pi) and in Whom Last Prior Therapy with Lenalidomide (LEN) FailedBLOOD, 2017, 130Siegel, DavidSchiller, Gary J.Song, Kevin W.Agajanian, RichyStockerl-Goldstein, KetihKaya, HakanSebag, MichaelSamaras, ChristyMalek, EhsanTalamo, GiampaoloSeet, Christopher S.Mouro, JorgeZafar, FaizaChung, WeiyuanSrinivasan, ShankarQian, MaxAgarwal, AmitThakurta, AnjanBahlis, Nizar J.
- [36] The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory DrugsBLOOD, 2019, 134Grzasko, NorbertKnop, StefanGoldschmidt, HartmutRaab, Marc S.Durig, JanBringhen, SaraD'Agostino, MattiaGamberi, BarbaraRivolti, ElenaVacca, AngeloRia, RobertoJurczyszyn, ArturAcosta, Jorge CastellanoLang, DorisLemaillet, GuySudhir, BansodSzarejko, Monika
- [37] MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal AntibodyBLOOD, 2022, 140 : 7292 - 7293Kumar, Shaji K.Garfall, Alfred L.Trudel, SuzanneOcio, Enrique M.Scott, EmmaHuang, LinMa, XuewenOlyslager, YunsiThakkar, PayalPei, LixiaHeuck, ChristophTerpos, Evangelos
- [38] Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practiceHAEMATOLOGICA, 2023, 108 (08) : 2192 - 2204Mateos, Maria-VictoriaWeisel, KatjaMartin, ThomasBerdeja, Jesus G.Jakubowiak, AndrzejStewart, A. KeithJagannath, SundarLin, YiDiels, JorisGhilotti, FrancescaThilakarathne, PushpikePerualila, Nolen J.Cabrieto, JedelynHaefliger, BenjaminErler-Yates, NicholaHague, ClareJackson, Carolyn C.Schecter, Jordan M.Strulev, VadimNesheiwat, ToniaPacaud, LidaEinsele, HermannMoreau, Philippe
- [39] Safety and Efficacy of Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) plus Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN) Based Treatment (Tx) FailureBLOOD, 2017, 130Siegel, DavidSchiller, Gary J.Samaras, ChristySebag, MichaelBerdeja, Jesus G.Ganguly, SiddharthaMatous, Jeffrey V.Song, Kevin W.Seet, Christopher S.Talamo, GiampaoloSrinivas, ShanthiAcosta-Rivera, MirelisBar, MichaelQuick, DonaldAnz, BertrandFonseca, GustavoReece, DonnaMouro, JorgeAgarwal, AmitZafar, FaizaQian, MaxThakurta, AnjanBahlis, Nizar J.
- [40] Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)BLOOD, 2015, 126 (23)Moreau, PhilippePalumbo, AntonioCorradini, PaoloCavo, MicheleDelforge, MichelWeisel, Katja C.Ocio, Enrique M.Cafro, AnnamariaRollig, ChristophKnop, Stefande Arriba, FelipeSimcock, MathewMiller, NeilSlaughter, AnaWatkins, LatishaHerring, JenniferBiyukov, TsvetanPeluso, TeresaZaki, Mohamed H.Dimopoulos, Meletios A.